Immune Characteristics Associated with Lymph Node Metastasis in Early-stage NSCLC

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2023 Sep 20

PMID 37728859

Authors

Ziyu Zhang

Li Li

Yang Gao

XiaoXiong Xiao

Liyan Ji

Zhipeng Zhou

Juan Jiang

Shiqing Liu

Jian An

Pengbo Deng

Nannan Du

Pansong Li

Xuefeng Xia

Chengping Hu

Min Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Tumor metastasis significantly impacts the prognosis of non-small cell lung cancer (NSCLC) patients, with lymph node (LN) metastasis being the most common and early form of spread. With the development of adjuvant immunotherapy, increasing attention has been paid to the tumor-draining lymph nodes（TDLN) in early-stage NSCLC, especially tumor-metastatic lymph nodes, which provides poor prognostic information but has potential benefits in adjuvant treatment.

Methods: We showed the remodeled immune environment in TDLNs through using TCR-seq to analyse 24 primary lung cancer tissues and 134 LNs from 24 lung cancer patients with or without LN metastasis. Additionally, we characterized the spatial profiling of immunocytes and tumor cells in TDLNs and primary tumor sites through using multi-IHC.

Results: We found the remodeled immune environment in TDLNs through analyzing primary lung cancer tissues and LNs from NSCLC patients with or without LN metastasis. Considering the intricate communication between tumor and immunocytes, we further subdivided TDLNs, revealing that metastasis-negative LNs from LN-metastatic patients (MNLN) exhibited greater immune activation, exhaustion, and memory in comparison to both metastasis-positive LNs (MPLN) and TDLNs from non-LN-metastatic patients (NMLN).

Conclusions: Our data indicate that LN metastasis facilitated tumor-specific antigen presentation in TDLNs and induces T cell priming, while existing tumor cells generate an immune-suppressive environment in MPLNs through multiple mechanisms. These findings contribute to a comprehensive understanding of the immunological mechanisms through which LN metastasis influences tumor progression and plays a role in immunotherapy for NSCLC patients.

References

Hirsch F, Scagliotti G, Mulshine J, Kwon R, Curran Jr W, Wu Y . Lung cancer: current therapies and new targeted treatments. Lancet. 2016; 389(10066):299-311. DOI: 10.1016/S0140-6736(16)30958-8. View

OMelia M, Manspeaker M, Thomas S . Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. Cancer Immunol Immunother. 2021; 70(8):2179-2195. PMC: 8286278. DOI: 10.1007/s00262-020-02792-5. View

Lee J, Torisu-Itakara H, Cochran A, Kadison A, Huynh Y, Morton D . Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res. 2005; 11(1):107-12. View

Mansfield A, Holtan S, Grotz T, Allred J, Jakub J, Erickson L . Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol. 2010; 24(4):487-94. DOI: 10.1038/modpathol.2010.227. View

van Pul K, Vuylsteke R, van de Ven R, Te Velde E, Rutgers E, van den Tol P . Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. J Immunother Cancer. 2019; 7(1):133. PMC: 6530094. DOI: 10.1186/s40425-019-0605-1. View

Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T . Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer. 2006; 106(6):1227-36. DOI: 10.1002/cncr.21729. View

van den Hout M, Koster B, Sluijter B, Molenkamp B, van de Ven R, van den Eertwegh A . Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence. Cancer Immunol Res. 2017; 5(11):969-977. DOI: 10.1158/2326-6066.CIR-17-0110. View

Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S . Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res. 2010; 16(16):4105-12. DOI: 10.1158/1078-0432.CCR-10-1073. View

Li G, Liu D, Cooper T, Kimchi E, Qi X, Avella D . Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol. 2016; 66(1):75-85. PMC: 5167655. DOI: 10.1016/j.jhep.2016.07.044. View

10.

Gonzalo Nunez N, Tosello Boari J, Ramos R, Richer W, Cagnard N, Anderfuhren C . Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat Commun. 2020; 11(1):3272. PMC: 7324591. DOI: 10.1038/s41467-020-17046-2. View

11.

Saw S, Ong B, Chua K, Takano A, Tan D . Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol. 2021; 22(11):e501-e516. DOI: 10.1016/S1470-2045(21)00383-1. View

12.

Chaft J, Shyr Y, Sepesi B, Forde P . Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):546-555. PMC: 8853628. DOI: 10.1200/JCO.21.01589. View

13.

Ling Y, Li N, Li L, Guo C, Wei J, Yuan P . Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. NPJ Precis Oncol. 2020; 4(1):32. PMC: 7708412. DOI: 10.1038/s41698-020-00135-2. View

14.

Molodtsov A, Khatwani N, Vella J, Lewis K, Zhao Y, Han J . Resident memory CD8 T cells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity. 2021; 54(9):2117-2132.e7. PMC: 9015193. DOI: 10.1016/j.immuni.2021.08.019. View

15.

Schenkel J, Herbst R, Canner D, Li A, Hillman M, Shanahan S . Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1 CD8 T cells in tumor-draining lymph nodes. Immunity. 2021; 54(10):2338-2353.e6. PMC: 8604155. DOI: 10.1016/j.immuni.2021.08.026. View

16.

Connolly K, Kuchroo M, Venkat A, Khatun A, Wang J, William I . A reservoir of stem-like CD8 T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol. 2021; 6(64):eabg7836. PMC: 8593910. DOI: 10.1126/sciimmunol.abg7836. View

17.

Binnewies M, Mujal A, Pollack J, Combes A, Hardison E, Barry K . Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4 T Cell Immunity. Cell. 2019; 177(3):556-571.e16. PMC: 6954108. DOI: 10.1016/j.cell.2019.02.005. View

18.

Lund A, Duraes F, Hirosue S, Raghavan V, Nembrini C, Thomas S . VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 2012; 1(3):191-9. DOI: 10.1016/j.celrep.2012.01.005. View

19.

Leone R, Powell J . Metabolism of immune cells in cancer. Nat Rev Cancer. 2020; 20(9):516-531. PMC: 8041116. DOI: 10.1038/s41568-020-0273-y. View

20.

Reticker-Flynn N, Zhang W, Belk J, Basto P, Escalante N, Pilarowski G . Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022; 185(11):1924-1942.e23. PMC: 9149144. DOI: 10.1016/j.cell.2022.04.019. View